Page 21 - CnO_228

d al c onsiglio d irettiv o

Oct 23;138(17):e484-e594. M, Zinman B, Bergenstal RM, Buse
17. Williams B, Mancia G, Spiering W, JB; LEADER Steering Committee;
Agabiti Rosei E, Azizi M, Burnier M, LEADER Trial Investigators. Liraglutide
Clement DL, Coca A, de Simone G, and Cardiovascular Outcomes in Type
Dominiczak A, Kahan T, Mahfoud F, 2 Diabetes. N Engl J Med. 2016 Jul
Redon J, Ruilope L, Zanchetti A, Kerins 28;375(4):311-22.
M, Kjeldsen SE, Kreutz R, Laurent S, 22. Marso SP, Bain SC, Consoli A,
Lip GYH, McManus R, Narkiewicz K, Eliaschewitz FG, Jódar E, Leiter LA,
Ruschitzka F, Schmieder RE, Shlyakhto Lingvay I, Rosenstock J, Seufert J,
E, Tsioufis C, Aboyans V, Desormais Warren ML, Woo V, Hansen O, Holst
I; Authors/Task Force Members. AG, Pettersson J, Vilsbøll T; SUSTAIN-6
2018 ESC/ESH Guidelines for the Investigators. Semaglutide and
management of arterial hypertension: Cardiovascular Outcomes in Patients
The Task Force for the management of with Type 2 Diabetes. N Engl J Med.
arterial hypertension of the European 2016 Nov 10;375(19):1834-1844.
Society of Cardiology and the European 23. Zinman B, Wanner C, Lachin
Society of Hypertension: The Task JM, Fitchett D, Bluhmki E, Hantel S,
Force for the management of arterial Mattheus M, Devins T, Johansen OE,
hypertension of the European Society Woerle HJ, Broedl UC, Inzucchi SE;
of Cardiology and the European Society EMPA-REG OUTCOME Investigators.
of Hypertension. J Hypertens. 2018 Empagliflozin, Cardiovascular
Oct;36(10):1953-2041. d Outcomes, and Mortality in Type 2
18. Grundy SM, Stone NJ, Bailey AL, Diabetes. N Engl J Med. 2015 Nov
Beam C, Birtcher KK, Blumenthal 26;373(22):2117-28.
RS, Braun LT, de Ferranti S, Faiella- 24. Neal B, Perkovic V, Mahaffey KW,
Tommasino J, Forman DE, Goldberg de Zeeuw D, Fulcher G, Erondu N,
R, Heidenreich PA, Hlatky MA, Jones Shaw W, Law G, Desai M, Matthews DR;
DW, Lloyd-Jones D, Lopez-Pajares N, CANVAS Program Collaborative Group.
Ndumele CE, Orringer CE, Peralta Canagliflozin and Cardiovascular and
CA, Saseen JJ, Smith SC Jr, Sperling Renal Events in Type 2 Diabetes. N Engl
L, Virani SS, Yeboah J. 2018 AHA/ J Med. 2017 Aug 17;377(7):644-657
ACC/AACVPR/AAPA/ABC/ACPM/ 25. Arnett DK, Blumenthal RS, Albert
ADA/AGS/APhA/ASPC/NLA/PCNA MA, Buroker AB, Goldberger ZD,
Guideline on the Management of Blood Hahn EJ, Himmelfarb CD, Khera A,
Cholesterol. Circulation. 2018 Nov Lloyd-Jones D, McEvoy JW, Michos
10:CIR0000000000000625. ED, Miedema MD, Muñoz D, Smith
19. Catapano AL, Graham I, De SC Jr, Virani SS, Williams KA Sr,
Backer G, Wiklund O, Chapman MJ, Yeboah J, Ziaeian B. 2019 ACC/AHA
Drexel H, Hoes AW, Jennings CS, Guideline on the Primary Prevention
Landmesser U, Pedersen TR, Reiner Ž, of Cardiovascular Disease. Circulation.
Riccardi G, Taskinen MR, Tokgozoglu 2019 Mar 17:CIR0000000000000678.
L, Verschuren WMM, Vlachopoulos 26. Grieve DJ, Cassidy RS, Green
C, Wood DA, Zamorano JL, Cooney BD. Emerging cardiovascular actions
MT; ESC Scientific Document Group. of the incretin hormone glucagon-
2016 ESC/EAS Guidelines for the like peptide-1: potential therapeutic
Management of Dyslipidaemias. Eur benefits beyond glycaemic control? Br J
Heart J. 2016 Oct 14;37(39):2999-3058. Pharmacol. 2009 Aug;157(8):1340-51.
20. Arnold SV, Lipska KJ, Li Y, McGuire 27. Pham D, Albuquerque Rocha N,
DK, Goyal A, Spertus JA, Kosiborod M. McGuire DK, Neeland IJ. Impact of
Prevalence of glucose abnormalities empagliflozin in patients with diabetes
among patients presenting with an and heart failure. Trends Cardiovasc
acute myocardial infarction. Am Heart Med. 2017 Feb;27(2):144-151
J. 2014 Oct;168(4):466-470.e1.
21. Marso SP, Daniels GH, Brown-
Frandsen K, Kristensen P, Mann JF,
Nauck MA, Nissen SE, Pocock S, Poulter
NR, Ravn LS, Steinberg WM, Stockner

19